Who
Gwenn Hansen
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Nurix Therapeutics.
In numbers
- Trades disclosed
- 223
- Buys
- 0
- Sells
- 39
- Bought
- $0
- Sold
- $2.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Nov 2020
- Last trade
- 15 Oct 2026
- Last filed
- 15 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 15 Oct 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,7011,452 at $1.86 | filing |
| 15 Oct 2026filed 15 Oct 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K1,452 at $25.00 | filing |
| 15 Oct 2026filed 15 Oct 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,452 at $0.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,7011,452 at $1.86 | filing |
| 1 Sep 2026filed 1 Sep 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K1,452 at $25.47 | filing |
| 1 Sep 2026filed 1 Sep 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,452 at $0.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,452 at $0.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,7011,452 at $1.86 | filing |
| 1 Sep 2026filed 1 Sep 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K1,452 at $25.47 | filing |
| 5 Aug 2026filed 5 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $8,1024,356 at $1.86 | filing |
| 5 Aug 2026filed 5 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $109K4,356 at $25.00 | filing |
| 5 Aug 2026filed 5 Aug 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,356 at $0.00 | filing |
| 5 Aug 2026filed 5 Aug 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,356 at $0.00 | filing |
| 5 Aug 2026filed 5 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $8,1024,356 at $1.86 | filing |
| 5 Aug 2026filed 5 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $109K4,356 at $25.00 | filing |
| 4 Aug 2026filed 5 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K1,500 at $23.87 | filing |
| 4 Aug 2026filed 5 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $64K2,611 at $24.64 | filing |
| 4 Aug 2026filed 5 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K1,500 at $23.87 | filing |
| 4 Aug 2026filed 5 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $64K2,611 at $24.64 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
News
Nurix Therapeutics (NASDAQ:NRIX) Director Julia Gregory Sells 22,583 Shares of Company StockNRIX · dailypolitical.com · 15 Oct 2026Nurix Therapeutics Q3 2026 Earnings: Key Financials RevealedNRIX · sci-tech-today.com · 13 Oct 2026Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNRIX · manilatimes.net · 12 Oct 2026
0 headlines in the last 90 days name Gwenn Hansen; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.